Cidara Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Cidara Therapeutics generated cash of -$22,432,000, which is more than the previous year. Cash used in financing activities reached the amount of $25,984,000 last year. Net change in cash is therefore $3,047,000.
Cash Flow
| 2014 | -7.71M | -991K | 31.31M |
|---|---|---|---|
| 2015 | -25.95M | -46.08M | 111.81M |
| 2016 | -39.77M | 25.48M | 37.09M |
| 2017 | -49.90M | 4.47M | 20.88M |
| 2018 | -56.70M | 14.30M | 56.15M |
| 2019 | -28.53M | -35K | 14.27M |
| 2020 | -54.41M | -186K | 37.27M |
| 2021 | -25.23M | -41K | 44.59M |
| 2022 | -28.47M | -118K | -951K |
| 2023 | -22.43M | -505K | 25.98M |
CDTX Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 32.73M | 62.27M | 42.94M | 60.26M | 74.56M | 60.81M | 85.36M | 62.56M | 22.79M | 185K |
Operating activities | ||||||||||
Net income | -22.93M | -29.79M | -42.46M | -72.11M | -41.09M | -59.01M | -55.72M | -48.16M | -32.19M | -11.89M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 118K | 1.22M | -1.23M | 229K | 375K | 523K | 667K | 732K | 461K | 179K |
Stock-based compensation expense | 3.06M | 3.53M | 4.01M | 4.09M | 5.07M | 0 | 5.71M | 4.34M | 3.03M | 232K |
| Deferred income tax benefit | 3.06M | 3.53M | 4.01M | 4.09M | 5.07M | 0 | 5.71M | 4.34M | 3.03M | 232K |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | -10.41M | -477K | 5.81M | -11.16M | -10K | 0 | 0 | 0 | 0 | 0 |
Inventories | -6.09M | 0 | 1.09M | -6.59M | 10K | 0 | 0 | 0 | 0 | 0 |
Accounts payable | 8.88M | -2.37M | -1.09M | 6.59M | -784K | -59K | 642K | 1.91M | 2.14M | 0 |
Cash generated by operating activities | -22.43M | -28.47M | -25.23M | -54.41M | -28.53M | -56.70M | -49.90M | -39.77M | -25.95M | -7.71M |
Investing activities | ||||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | -14.54M | -19.52M | -69.61M | -54.91M | 0 |
Investments In Property Plant And Equipment | -505K | -118K | -41K | -186K | -35K | -177K | -306K | -401K | -1.17M | -991K |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | -505K | -118K | -41K | -186K | -35K | 14.30M | 4.47M | 25.48M | -46.08M | -991K |
Financing activities | ||||||||||
Common Stock Issued | 25.96M | 2.36M | 49.03M | 40.22M | 14.29M | 6.44M | 20.73M | 26.62M | 69.50M | 10K |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | -79K | 175K | 0 | 0 |
Repayments of term debt | 0 | -2.59M | -4.44M | -2.96M | 0 | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | 25.98M | -951K | 44.59M | 37.27M | 14.27M | 56.15M | 20.88M | 37.09M | 111.81M | 31.31M |
Net Change In Cash | 3.04M | -29.54M | 19.32M | -17.31M | -14.29M | 13.74M | -24.55M | 22.80M | 39.76M | 22.61M |
Cash at end of period | 35.77M | 32.73M | 62.27M | 42.94M | 60.26M | 74.56M | 60.81M | 85.36M | 62.56M | 22.79M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |